ARMY AL&T
HOME TEST
A COVID-19 home test kit. The DA2 screening and diagnostics team enabled the manufacturing expansion of two at- home testing capabilities that are expected to produce 600,000 at-home tests per day. (Image by iStock, clubfoto)
and doctor’s offices, with an emphasis on testing underserved populations as well as senior citizens in assisted living or retire- ment communities. Tis resulted in three investments to increase manufacturing for these point-of-care tests to 10 million tests per month. Te team anticipates further increasing production capacity of point- of-care tests by 30 million per month in the near term.
Recognizing that additional testing oppor- tunities existed, the DA2 screening and diagnostics team worked with Office of the Assistant Secretary for Health and representatives from the White House Coronavirus Task Force and the COVID- 19 Health Equity Task Force to identify, invest in, expand production of, and procure COVID-19 tests with an FDA emergency use authorization for use by individuals from the convenience of their homes. Not only did these invest- ments make access to testing easier in the U.S., they also reduced the potential for exposure of high-risk individuals receiv- ing testing from a clinic, doctor’s office or laboratory. Trough their efforts, the team picked up the torch on two research and development investments by the Biomed- ical Advanced Research and Development
Authority and the National Institutes of Health’s Rapid Acceleration of Diagnostics initiative, and funded the manufacturing expansion of two at-home testing capabil- ities, expected to provide the capacity to produce 600,000 at-home tests per day.
Te team manages a testing and diagnos- tics portfolio of $2.1 billion in investments, with an expected $1.1 billion in near-term awards. Tese investments are expected to yield the tests and testing supplies required by HHS and the nation, including a total expected increase of 120 million tests per month. Tis represents the majority of the target increase in U.S. testing capability defined by HHS.
BRING IT ON HOME Another major hurdle during the pandemic revolved around international sourcing of supplies. With the lack of availability, transportation issues and governmental restrictions, the team understood that onshore production was one of the keys to increasing capacity. Te DA2 screen- ing and diagnostics team received funding from the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) to build a team of military, civil- ian and contractor personnel to provide
continued industrial base expansion exper- tise and counsel on acquisition efforts, and to maintain situational awareness regard- ing availability of industry resources. Tese integration efforts advanced the development of the Rapid Acceleration of Diagnostics, the Biomedical Advanced Research and Development Authority and the Office of the Assistant Secretary for Health and ASPR initiatives, resolved urgent test distribution crises and aligned industry partners to enable development, and ultimately delivery, of the next diag- nostic capability.
Throughout the COVID-19 pandemic the DA2 screening and development team has always delivered.
https://asc.ar my.mil 81
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176
